BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Kremer AE, Le Cleac’h A, Lemoinne S, Wolf K, De Chaisemartin L, Chollet-martin S, Humbert L, Rainteau D, Poupon R, Rousseau A, Chazouillères O, Corpechot C. Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. Gut 2019;68:1902-3. [DOI: 10.1136/gutjnl-2018-317426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
2 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yu K, Li P, Xu T, Xu J, Wang K, Chai J, Zhao D, Liu Y, Wang Y, Ma J, Fan L, Guo S, Li Z, Li M, Wang Z. Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis. Pathol Res Pract 2021;217:153291. [PMID: 33249399 DOI: 10.1016/j.prp.2020.153291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zhao DT, Liu YM, Han Y, Zhang HP, Zhao Y, Yan HP. Fluctuations of antimitochondrial antibodies and anti-gp210 antibody in a patient with primary biliary cholangitis and Sjögren syndrome with subsequent autoimmune hemolytic anemia: A case report. Medicine (Baltimore) 2020;99:e18856. [PMID: 32011506 DOI: 10.1097/MD.0000000000018856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Corpechot C. Clinical Trials in PBC Going Forward. Semin Liver Dis 2019;39:e1-6. [DOI: 10.1055/s-0039-1687852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Chen YS, Liu HM, Lee TY. Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. Cells. 2019;8:253. [PMID: 30884843 DOI: 10.3390/cells8030253] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
7 Freer A, Williams F, Durman S, Hayden J, Trivedi PJ, Armstrong MJ. Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial. BMJ Open Gastroenterol 2021;8:e000579. [PMID: 33707216 DOI: 10.1136/bmjgast-2020-000579] [Reference Citation Analysis]
8 Lin H, Zhou C, Hou Y, Li Q, Qiao G, Wang Y, Huang Z, Niu J. Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid. Front Pharmacol 2019;10:1515. [PMID: 31920680 DOI: 10.3389/fphar.2019.01515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Sun C, Xiao X, Yan L, Sheng L, Wang Q, Jiang P, Lian M, Li Y, Wei Y, Zhang J, Chen Y, Li B, Li Y, Huang B, Li Y, Peng Y, Chen X, Fang J, Qiu D, Hua J, Tang R, Leung P, Gershwin ME, Miao Q, Ma X. Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker? Journal of Autoimmunity 2019;99:33-8. [DOI: 10.1016/j.jaut.2019.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
10 Hirschfield GM, Chazouillères O, Cortez-Pinto H, Macedo G, de Lédinghen V, Adekunle F, Carbone M. A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients. Expert Rev Gastroenterol Hepatol 2021;15:929-39. [PMID: 34233565 DOI: 10.1080/17474124.2021.1945919] [Reference Citation Analysis]
11 Parés A, Shiffman M, Vargas V, Invernizzi P, Malecha ES, Liberman A, MacConell L, Hirschfield G. Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver Int 2020;40:1121-9. [PMID: 32145129 DOI: 10.1111/liv.14429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
12 Kumar A, Al-hassi HO, Steed H, Phipps O, Brookes MJ, Nakamura M. Bile Acids and the Microbiome: Making Sense of This Dynamic Relationship in Their Role and Management in Crohn’s Disease. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/8416578] [Reference Citation Analysis]
13 Shah RA, Kowdley KV. Current and potential treatments for primary biliary cholangitis. The Lancet Gastroenterology & Hepatology 2020;5:306-15. [DOI: 10.1016/s2468-1253(19)30343-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
14 Phaw NA, Dyson JK, Jones D. Emerging drugs for the treatment of primary biliary cholangitis. Expert Opin Emerg Drugs 2020;25:101-12. [PMID: 32253941 DOI: 10.1080/14728214.2020.1751814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Corpechot C, Poupon R, Chazouillères O. New treatments/targets for primary biliary cholangitis. JHEP Rep 2019;1:203-13. [PMID: 32039371 DOI: 10.1016/j.jhepr.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
16 Leitch AC, Abdelghany TM, Probert PM, Dunn MP, Meyer SK, Palmer JM, Cooke MP, Blake LI, Morse K, Rosenmai AK, Oskarsson A, Bates L, Figueiredo RS, Ibrahim I, Wilson C, Abdelkader NF, Jones DE, Blain PG, Wright MC. The toxicity of the methylimidazolium ionic liquids, with a focus on M8OI and hepatic effects. Food Chem Toxicol 2020;136:111069. [PMID: 31883992 DOI: 10.1016/j.fct.2019.111069] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
17 Zhang Z, Fu W, Wang M, Niu L, Liu B, Jiao Y, Liu X. IgG4-related inflammatory pseudotumor of the brain parenchyma: a case report and literature review. Acta Neurol Belg 2018;118:617-27. [DOI: 10.1007/s13760-018-1027-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
18 Leitch AC, Ibrahim I, Abdelghany TM, Charlton A, Roper C, Vidler D, Palmer JM, Wilson C, Jones DE, Blain PG, Wright MC. The methylimidazolium ionic liquid M8OI is detectable in human sera and is subject to biliary excretion in perfused human liver. Toxicology 2021;459:152854. [PMID: 34271081 DOI: 10.1016/j.tox.2021.152854] [Reference Citation Analysis]
19 Zhao M, Zhang M, Zhou S, Shi B, Wei Y, Huang F, Wang J, Huang J, Qiao L. Transverse myelitis associated with primary biliary cirrhosis: clinical, laboratory, and neuroradiological features. Int J Neurosci 2020;:1-8. [PMID: 32842840 DOI: 10.1080/00207454.2020.1815735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Hao YL, Bian ZL, Ju LL, Liu Y, Qin G. RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis. Dig Dis Sci 2020;65:470-9. [PMID: 31377883 DOI: 10.1007/s10620-019-05758-5] [Reference Citation Analysis]
21 Sarcognato S, Sacchi D, Grillo F, Cazzagon N, Fabris L, Cadamuro M, Cataldo I, Covelli C, Mangia A, Guido M. Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis. Pathologica 2021;113:170-84. [PMID: 34294935 DOI: 10.32074/1591-951X-245] [Reference Citation Analysis]
22 Zou M, Wang A, Wei J, Cai H, Yu Z, Zhang L, Wang X. An insight into the mechanism and molecular basis of dysfunctional immune response involved in cholestasis. Int Immunopharmacol 2021;92:107328. [PMID: 33412394 DOI: 10.1016/j.intimp.2020.107328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Mulinacci G, Palermo A, Invernizzi P, Carbone M. Old and novel prognostic biomarkers in primary biliary cholangitis. Expert Opinion on Orphan Drugs 2021;9:123-31. [DOI: 10.1080/21678707.2021.1927700] [Reference Citation Analysis]
24 Contreras-Omaña R, Velarde-Ruiz Velasco JA, Castro-Narro GE, Trujillo-Benavides O, Zamarripa-Dorsey F, Reyes-Dorantes AA, Muñoz-Espinosa L, Aiza-Haddad I, Castillo-Barradas M, Cerda-Reyes E, Cisneros-Garza LE, Flores-Calderón J, García-Jiménez ES, Higuera-de-la-Tijera MF, Lira-Pedrín MA, Marquez-Guillén E, Moctezuma-Velázquez C, Moreno-Alcántar R, Noyola-Cedillo SG, Pérez-Hernández JL, Ramos-Gómez MV, Remes-Troche JM, Rizo-Robles MT, Rodríguez-Hernández H. Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00130-4. [PMID: 34866042 DOI: 10.1016/j.rgmxen.2021.04.003] [Reference Citation Analysis]
25 Shah NM, Malhotra AM, Kaltsakas G. Sleep disorder in patients with chronic liver disease: a narrative review. J Thorac Dis 2020;12:S248-60. [PMID: 33214928 DOI: 10.21037/jtd-cus-2020-012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
26 Lee J, Hong EM, Kim JH, Kim JH, Jung JH, Park SW, Koh DH, Jang HJ. Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition. Mol Biol Rep 2021;48:6231-40. [PMID: 34392440 DOI: 10.1007/s11033-021-06331-y] [Reference Citation Analysis]
27 Alvaro D, Carpino G, Craxi A, Floreani A, Moschetta A, Invernizzi P. Primary biliary cholangitis management: controversies, perspectives and daily practice implications from an expert panel. Liver Int 2020;40:2590-601. [DOI: 10.1111/liv.14627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Akberova D, Kiyasov IA, Abdulganieva D, Odintsova A. Changes of Intestinal Permeability («Triple Sugar Test») in Patients with Primary Biliary Cholangitis. BioNanoSci . [DOI: 10.1007/s12668-022-00944-8] [Reference Citation Analysis]
29 Chapman RW, Lynch KD. Obeticholic acid-a new therapy in PBC and NASH. Br Med Bull 2020;133:95-104. [PMID: 32282030 DOI: 10.1093/bmb/ldaa006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
30 Yan Y, Xing X, Lu Q, Wang X, Men R, Luo X, Yang L. Two-dimensional shear wave elastography for screening varices in Asian patients with primary biliary cholangitis. Expert Rev Gastroenterol Hepatol 2021;15:965-73. [PMID: 33513034 DOI: 10.1080/17474124.2021.1884071] [Reference Citation Analysis]
31 Cristoferi L, Calvaruso V, Overi D, Viganò M, Rigamonti C, Degasperi E, Cardinale V, Labanca S, Zucchini N, Fichera A, Di Marco V, Leutner M, Venere R, Picciotto A, Lucà M, Mulinacci G, Palermo A, Gerussi A, D'Amato D, Elisabeth O'Donnell S, Cerini F, De Benedittis C, Malinverno F, Ronca V, Mancuso C, Cazzagon N, Ciaccio A, Barisani D, Marzioni M, Floreani A, Alvaro D, Gaudio E, Invernizzi P, Carpino G, Nardi A, Carbone M; Italian PBC Registry. Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach. Hepatology 2021. [PMID: 33724515 DOI: 10.1002/hep.31810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Dalekos GN, Gatselis NK. Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases. Arch Immunol Ther Exp (Warsz) 2019;67:197-211. [PMID: 31165900 DOI: 10.1007/s00005-019-00550-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
33 Li Y, Tang R, Ma X. Epigenetics of Primary Biliary Cholangitis. Adv Exp Med Biol 2020;1253:259-83. [PMID: 32445099 DOI: 10.1007/978-981-15-3449-2_10] [Reference Citation Analysis]
34 Appanna G, Kallis Y. An update on the management of cholestatic liver diseases. Clin Med (Lond) 2020;20:513-6. [PMID: 32934048 DOI: 10.7861/clinmed.2020-0697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bonaguri C, Melegari A, Picanza A, Russo A, De Santis E, Trenti T, Parmeggiani M, Belloni L, Savi E, de'Angelis GL, Gaiani F, Ferrari C, Lippi G. Association of solid-phase assays to the indirect immunofluorescence in primary biliary cholangitis diagnosis: Results of an Italian multicenter study. Autoimmunity Reviews 2019;18:102389. [DOI: 10.1016/j.autrev.2019.102389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Dyson JK, Jeffreys Jones DE. Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management? Gastroenterology 2021;160:649-51. [PMID: 33340537 DOI: 10.1053/j.gastro.2020.12.019] [Reference Citation Analysis]
37 Fujita K, Nomura T, Morishita A, Shi T, Oura K, Tani J, Kobara H, Tsutsui K, Himoto T, Masaki T. Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis. J Clin Med 2019;8:E1258. [PMID: 31430975 DOI: 10.3390/jcm8081258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
38 Zhou X, Kailemia MJ, Sun Y, Shuai Z, Yang GX, Dhaliwal S, Cristoferi L, Leung PSC, Invernizzi P, Bowlus CL, Lebrilla CB, Ansari AA, Ridgway WM, Zhang W, Gershwin ME. Glycomic analysis of antibody indicates distinctive glycosylation profile in patients with autoimmune cholangitis. J Autoimmun 2020;113:102503. [PMID: 32546343 DOI: 10.1016/j.jaut.2020.102503] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Yang Z, Liang Y. New-onset primary biliary cholangitis in anti-mitochondrial antibody-positive patients may be underestimated without liver biopsy. J Intern Med 2020;287:580-1. [PMID: 32034820 DOI: 10.1111/joim.13023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Liu Y, Tian S, Jia G, Han Z, Guo C, Shang Y, Han Y. Symptoms Burden and Health-related Quality of Life in Chinese Patients with Primary Biliary Cholangitis. J Clin Transl Hepatol 2021;9:860-7. [PMID: 34966649 DOI: 10.14218/JCTH.2020.00119] [Reference Citation Analysis]
41 Keitel V, Dröge C, Häussinger D. Targeting FXR in Cholestasis. Handb Exp Pharmacol 2019;256:299-324. [PMID: 31201556 DOI: 10.1007/164_2019_231] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
42 Sayar S, Gokcen P, Aykut H, Adali G, Doganay HL, Ozdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Sisli Etfal Hastan Tip Bul 2021;55:412-8. [PMID: 34712085 DOI: 10.14744/SEMB.2021.95825] [Reference Citation Analysis]
43 Zhao Y, Yin Z, Du H, Huang K, Zhang F, Chen H. The latest research trends in primary biliary cholangitis: a bibliometric analysis. Clin Exp Med 2022. [PMID: 35389157 DOI: 10.1007/s10238-022-00825-0] [Reference Citation Analysis]
44 Martin ML, Stassek L, Blum SI, Joshi AV, Jones D. Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis. J Patient Rep Outcomes 2019;3:2. [PMID: 30645706 DOI: 10.1186/s41687-018-0090-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 March-Rodriguez A, Marcantonio O, Olmos-Alpiste F, Pujol RM. Acquired palmoplantar keratoderma associated with primary biliary cholangitis: Complete and persistent resolution after ursodeoxycholic acid treatment. Australas J Dermatol 2021. [PMID: 34905624 DOI: 10.1111/ajd.13765] [Reference Citation Analysis]
46 Zhang H, Liu Y, Li Z, Liang N, Zhou X, Nie X, Zhang T, Qi W. Amyotrophic Lateral Sclerosis and Primary Biliary Cirrhosis Overlap Syndrome: Two Cases Report. Front Neurol 2019;10:890. [PMID: 31474934 DOI: 10.3389/fneur.2019.00890] [Reference Citation Analysis]
47 Abdelghany TM, Leitch AC, Nevjestić I, Ibrahim I, Miwa S, Wilson C, Heutz S, Wright MC. Emerging risk from "environmentally-friendly" solvents: Interaction of methylimidazolium ionic liquids with the mitochondrial electron transport chain is a key initiation event in their mammalian toxicity. Food Chem Toxicol 2020;145:111593. [PMID: 32777338 DOI: 10.1016/j.fct.2020.111593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Corrigan M, Hirschfield G, Greenfield S, Parry J. Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise. BMJ Open Gastroenterol 2019;6:e000226. [PMID: 31321066 DOI: 10.1136/bmjgast-2018-000226] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, You H, Kong Y, Jia J. Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterol Res Pract. 2019;2019:8959103. [PMID: 31281353 DOI: 10.1155/2019/8959103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
50 Guatibonza-García V, Gaete PV, Pérez-Londoño A, Puerto-Baracaldo DK, Gutiérrez-Romero SA, Mendivil CO, Tapias M. Poor performance of anti-mitochondrial antibodies for the diagnosis of primary biliary cholangitis in female Colombian patients: A single-center study. World J Gastroenterol 2021; 27(29): 4890-4899 [PMID: 34447233 DOI: 10.3748/wjg.v27.i29.4890] [Reference Citation Analysis]
51 Alrubaiy L, Mells G, Flack S, Bosomworth H, Hutchings H, Williams J, Jones D; UK-PBC Research Consortium. PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis. Aliment Pharmacol Ther 2019;50:1223-31. [PMID: 31664722 DOI: 10.1111/apt.15554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
52 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
53 Gazda J, Janicko M, Drazilova S, Grgurevic I, Kanizaj TF, Koller T, Bodorovska B, Mijic M, Mikolasevic I, Stromar IK, Kucinsky B, Gazda M, Jarcuska P. External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. Can J Gastroenterol Hepatol 2021;2021:9928065. [PMID: 34258254 DOI: 10.1155/2021/9928065] [Reference Citation Analysis]
54 Wang Z, Peng C, Wang P, Sui J, Wang Y, Sun G, Liu M. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol 2020;55:1333-40. [PMID: 33021858 DOI: 10.1080/00365521.2020.1829030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Jia D, Wang YY, Wang P, Huang Y, Liang DY, Wang D, Cheng C, Zhang C, Guo L, Liang P, Wang Y, Jia Y, Li C. SVIP alleviates CCl4-induced liver fibrosis via activating autophagy and protecting hepatocytes. Cell Death Dis 2019;10:71. [PMID: 30683843 DOI: 10.1038/s41419-019-1311-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
56 Lin L, Lin B, Lan Q, Liu L, Lu J, Zhang X, Zheng S, Xue Y, Granito A. Presence of Serum Antinuclear Antibodies Does Not Impact Outcomes in HBV-Related Acute-on-Chronic Liver Failure. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/7981338] [Reference Citation Analysis]
57 Ahn DW. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis]. Korean J Gastroenterol 2020;75:246-56. [PMID: 32448856 DOI: 10.4166/kjg.2020.75.5.246] [Reference Citation Analysis]
58 You H, Ma X, Efe C, Wang G, Jeong SH, Abe K, Duan W, Chen S, Kong Y, Zhang D, Wei L, Wang FS, Lin HC, Yang JM, Tanwandee T, Gani RA, Payawal DA, Sharma BC, Hou J, Yokosuka O, Dokmeci AK, Crawford D, Kao JH, Piratvisuth T, Suh DJ, Lesmana LA, Sollano J, Lau G, Sarin SK, Omata M, Tanaka A, Jia J. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 2022. [PMID: 35119627 DOI: 10.1007/s12072-021-10276-6] [Reference Citation Analysis]
59 Naz I, Khan MR, Zai JA, Batool R, Zahra Z, Tahir A. Pilea umbrosa ameliorate CCl4 induced hepatic injuries by regulating endoplasmic reticulum stress, pro-inflammatory and fibrosis genes in rat. Environ Health Prev Med 2020;25:53. [PMID: 32917140 DOI: 10.1186/s12199-020-00893-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Gerussi A, D’amato D, Cristoferi L, O’donnell SE, Carbone M, Invernizzi P. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies. Annals of Hepatology 2020;19:5-16. [DOI: 10.1016/j.aohep.2019.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Manesis EK, Schina M, Vafiadis I, Gatos I, Theotokas J, Zoumpoulis P, Drazinos P, Ketikoglou J, Delladetsima IK, Tiniakos DG. Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis. Scand J Gastroenterol 2021;:1-7. [PMID: 34375562 DOI: 10.1080/00365521.2021.1928277] [Reference Citation Analysis]
62 Leung KK, Deeb M, Hirschfield GM. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. [DOI: 10.1111/apt.16023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
63 Zheng Y, Ran Y, Zhang H, Wang B, Zhou L. The Microbiome in Autoimmune Liver Diseases: Metagenomic and Metabolomic Changes. Front Physiol 2021;12:715852. [PMID: 34690796 DOI: 10.3389/fphys.2021.715852] [Reference Citation Analysis]
64 Mazzetti M, Marconi G, Mancinelli M, Benedetti A, Marzioni M, Maroni L. The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. J Clin Med 2021;10:1763. [PMID: 33919600 DOI: 10.3390/jcm10081763] [Reference Citation Analysis]
65 Yang Y, Liu S, Gao H, Wang P, Zhang Y, Zhang A, Jia Z, Huang S. Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2. Free Radic Biol Med 2020;152:821-37. [PMID: 32004633 DOI: 10.1016/j.freeradbiomed.2020.01.182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
66 Patel R, Portone G, Lambert JA, Mak S, Alrubaiy L. Disease-modifying therapies and symptomatic management for primary biliary cholangitis. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 34817254 DOI: 10.12968/hmed.2021.0247] [Reference Citation Analysis]
67 Gao L, Wang L, Woo E, He X, Yang G, Bowlus C, Leung PSC, Gershwin ME. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends. Clin Rev Allergy Immunol. 2019;. [PMID: 31713023 DOI: 10.1007/s12016-019-08772-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
68 Gao Y, Li L, Li B, Zhan Y. Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:8829510. [PMID: 33511089 DOI: 10.1155/2021/8829510] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Couto CA, Terrabuio DRB, Cançado ELR, Porta G, Levy C, Silva AEB, Bittencourt PL, Carvalho Filho RJD, Chaves DM, Miura IK, Codes L, Faria LC, Evangelista AS, Farias AQ, Gonçalves LL, Harriz M, Lopes EPDA, Luz GO, Oliveira PMC, Oliveira EMG, Schiavon JLN, Sevá-pereira T. UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER. Arq Gastroenterol 2019;56:232-41. [DOI: 10.1590/s0004-2803.201900000-43] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Lin CY, Cheng YT, Chang ML, Chien RN. The extrahepatic events of Asian patients with primary biliary cholangitis: A 30-year cohort study. Sci Rep 2019;9:7577. [PMID: 31110209 DOI: 10.1038/s41598-019-44081-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 Abbas N, Quraishi MN, Trivedi P. Emerging drugs for the treatment of primary sclerosing cholangitis. Curr Opin Pharmacol 2021;62:23-35. [PMID: 34894541 DOI: 10.1016/j.coph.2021.11.003] [Reference Citation Analysis]
72 Wang W, Tian SL, Jin D, Liu B, Wang W, Chang H, Chen C, Yu Z, Wang YZ, Li YL. The role of bile acid subtypes in the diagnosis of cholangiocarcinoma. Asia Pac J Clin Oncol 2021. [PMID: 34161672 DOI: 10.1111/ajco.13588] [Reference Citation Analysis]
73 Prieto J, Banales JM, Medina JF. Primary biliary cholangitis: pathogenic mechanisms. Curr Opin Gastroenterol 2021;37:91-8. [PMID: 33332913 DOI: 10.1097/MOG.0000000000000703] [Reference Citation Analysis]
74 Warnes T, Roberts S, Smith A, Haboubi N, McMahon RF. Liver biopsy in primary biliary cholangitis: is sinusoidal fibrosis the missing key? J Clin Pathol 2019;72:669-76. [PMID: 31371396 DOI: 10.1136/jclinpath-2019-205958] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
75 Robles-Díaz M, Nezic L, Vujic-Aleksic V, Björnsson ES. Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. Front Pharmacol 2021;12:744488. [PMID: 34776963 DOI: 10.3389/fphar.2021.744488] [Reference Citation Analysis]
76 Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019;105:102328. [PMID: 31548157 DOI: 10.1016/j.jaut.2019.102328] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
77 Arvaniti P, Zachou K, Lyberopoulou A, Gatselis NK, Brooks WH, Dalekos GN, Renaudineau Y. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren's Syndrome and Primary Biliary Cholangitis. Epigenomes 2019;3:15. [PMID: 34968227 DOI: 10.3390/epigenomes3030015] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
78 Goet JC, Hirschfield GM. Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines. Frontline Gastroenterol 2019;10:316-9. [PMID: 31281627 DOI: 10.1136/flgastro-2018-101109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
79 Cabrera-Rubio R, Patterson AM, Cotter PD, Beraza N. Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice. Sci Rep 2019;9:12324. [PMID: 31444478 DOI: 10.1038/s41598-019-48784-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
80 Smith A, Giles B, Aspinall RJ. Primary biliary cholangitis: advances in understanding and management. Br J Hosp Med. [DOI: 10.12968/hmed.2021.0450] [Reference Citation Analysis]
81 Li X, Liao M, Pan Q, Xie Q, Yang H, Peng Y, Li Q, Qu J, Chai J. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review. Eur J Gastroenterol Hepatol 2020;32:1116-22. [PMID: 32649329 DOI: 10.1097/MEG.0000000000001785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Costa V, Moreira M, Costa R, Fontes J. Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report. J Med Cases 2021;12:131-3. [PMID: 34434444 DOI: 10.14740/jmc3623] [Reference Citation Analysis]
83 Maurice JB, Thorburn D. Precision medicine in primary sclerosing cholangitis. J Dig Dis 2019;20:346-56. [PMID: 31099965 DOI: 10.1111/1751-2980.12788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
84 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Abdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse AW, Schramm C, Weiler-Normann C. Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. Scand J Gastroenterol 2019;54:1391-6. [PMID: 31692389 DOI: 10.1080/00365521.2019.1683226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
86 Dyson JK, Blain A, Foster Shirley MD, Hudson M, Rushton S, Jeffreys Jones DE. Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Rep 2021;3:100202. [PMID: 33474546 DOI: 10.1016/j.jhepr.2020.100202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
87 Burghart L, Halilbasic E, Schwabl P, Simbrunner B, Stättermayer AF, Petrenko O, Scheiner B, Bauer D, Pinter M, Boztug K, Mandorfer M, Trauner M, Reiberger T. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. J Gastroenterol 2021. [PMID: 34893924 DOI: 10.1007/s00535-021-01839-3] [Reference Citation Analysis]
88 Wetten A, Jones DEJ, Dyson JK. Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough? Expert Opin Pharmacother 2021;:1-5. [PMID: 34121570 DOI: 10.1080/14656566.2021.1940135] [Reference Citation Analysis]
89 Wang MN, Yu HT, Li YQ, Zeng Y, Yang S, Yang GP, Pei Q, Huang J. Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions. Drug Des Devel Ther 2021;15:185-93. [PMID: 33469270 DOI: 10.2147/DDDT.S289016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kempinska-Podhorodecka A, Adamowicz M, Chmielarz M, Janik MK, Milkiewicz P, Milkiewicz M. Vitamin-D Receptor-Gene Polymorphisms Affect Quality of Life in Patients with Autoimmune Liver Diseases. Nutrients. 2020;12. [PMID: 32727130 DOI: 10.3390/nu12082244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
91 Sivakumar M, Gandhi A, Shakweh E, Li YM, Safinia N, Smith BC, Marshall A, Turner L, Mukhopadhya A, Haboubi HN, Vincent R, Tan HK, Alrubaiy L, Jones DEJ. Widespread gaps in the quality of care for primary biliary cholangitis in UK. Frontline Gastroenterol 2022;13:32-8. [PMID: 34966531 DOI: 10.1136/flgastro-2020-101713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]